Study on GJB2: Potential Drug Target and Biomarker for Neurological Disorders

Target Name: GJB2

NCBI ID: G2706

GJB2

Study on GJB2: Potential Drug Target and Biomarker for Neurological Disorders

GJB2 (BAPS), a protein that is expressed in the brain, has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders. Its function and interactions with other proteins have been studied extensively in the scientific community, and its potential clinical applications are being investigated.

GJB2 is a member of the BAP (Brain-Specific Antigens) family, which includes several other proteins that are expressed in the brain and have been implicated in various neurological disorders. These proteins are characterized by the presence of a variable region that is specific for each individual patient, as well as a constant region that is shared among all BAP proteins.

GJB2 is expressed in various tissues of the body, including the brain, and has been shown to be involved in several important functions in the central nervous system (CNS). For example, GJB2 has been shown to play a role in the development and maintenance of the blood-brain barrier (BBB), which is responsible for protecting the brain from harmful substances that attempt to enter the brain.

Additionally, GJB2 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is critical for the function of the brain. GJB2 has been shown to interact with several neurotransmitters, including dopamine, serotonin, and GABA.

GJB2 has also been shown to be involved in the regulation of inflammation in the brain, which is an important factor in the development of various neurological disorders. For example, GJB2 has been shown to play a role in the regulation of the immune response in the brain, and has been shown to interact with several immune cells and molecules.

GJB2 has also been shown to be involved in the regulation of cell survival and proliferation, which is important for the development and maintenance of the brain. For example, GJB2 has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells are programmed to die.

GJB2 has been shown to be involved in several other important functions in the brain, including the regulation of neural development and plasticity, the regulation of motion and cognition, and the regulation of behavioral state.

GJB2 has also been shown to be a potential drug target for several neurological and psychiatric disorders. For example, GJB2 has been shown to be involved in the development and maintenance of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, GJB2 has been shown to be involved in the development of several psychiatric disorders, including depression and anxiety.

GJB2 has also been shown to be a potential biomarker for several neurological and psychiatric disorders. For example, GJB2 has been shown to be involved in the diagnosis of Alzheimer's disease, and has been shown to be decreased in the brains of individuals with Alzheimer's disease compared to those without the disease. Additionally, GJB2 has been shown to be involved in the diagnosis of Parkinson's disease, and has been shown to be decreased in the brains of individuals with Parkinson's disease compared to those without the disease.

GJB2 has also been shown to be involved in several therapeutic approaches for neurological and psychiatric disorders. For example, GJB2 has been shown to be a potential target for small molecule inhibitors, which have been shown to be effective in treating several neurological and psychiatric disorders. Additionally, GJB2 has been shown to be a potential target for monoclonal antibodies, which have been shown to be effective in treating several neurological and psychiatric disorders.

In conclusion, GJB2 is a protein that is expressed in the brain and has been shown to play

Protein Name: Gap Junction Protein Beta 2

Functions: Structural component of gap junctions (PubMed:17551008, PubMed:19340074, PubMed:21094651, PubMed:26753910, PubMed:16849369, PubMed:19384972). Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. They are formed by the docking of two hexameric hemichannels, one from each cell membrane (PubMed:17551008, PubMed:19340074, PubMed:21094651, PubMed:26753910). Small molecules and ions diffuse from one cell to a neighboring cell via the central pore (PubMed:21094651, PubMed:16849369, PubMed:19384972)

The "GJB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets